---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-040645"
form_type: "8-K"
ticker: "OGEN"
cik: "0001174940"
company_name: "ORAGENICS INC"
filed_at: "2026-08-28T21:06:48+00:00"
generated_at: "2026-08-28T21:08:24.158632+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Oragenics receives NYSE American delisting notice; equity $3.7M below needed thresholds

## Summary
- NYSE American deficiency letter dated Aug 26, 2026 citing non-compliance with Sections 1003(a)(ii)/(iii); equity $3.7M at June 30, 2026 vs $4M/$6M minimums.
- Compliance plan due Sept 25, 2026; cure period through Feb 25, 2028; OGEN shares get '.BC' (below compliance) designation.
- Phase IIa trial for ONP-002: 9 participants dosed across 3 Australian sites (Alfred Health, Mackay, Royal Adelaide Hospital).
- FDA Type B meeting responses received for July 2026 package; IND submission still targeted by end of 2026.

## SEC filing metadata
- accession: 0001493152-26-040645
- form_type: 8-K
- ticker: OGEN
- cik: 0001174940
- company_name: ORAGENICS INC
- filed_at: 2026-08-28T21:06:48+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1174940/000149315226040645/0001493152-26-040645-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1174940/000149315226040645/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-040645
- JSON: https://secwatch.observer/filing/0001493152-26-040645.json
- Plain text: https://secwatch.observer/filing/0001493152-26-040645.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.